The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation

NCT06561880 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

66

Enrollment

OTHER

Sponsor class

Conditions

FLT3 Gene Mutation
AML

Interventions

DRUG: Venetoclax
DRUG: Cytarabine
DRUG: Gilteritinib
DRUG: Azacitadine (AZA)

Sponsor

Institute of Hematology & Blood Diseases Hospital, China